TG Therapeutics: An Immunology Powerhouse | Latest News RSS feed

TG Therapeutics: An Immunology Powerhouse - Latest News


TG Therapeutics: An Immunology Powerhouse

Finances: Enough liquid assets to support the company until at least Q1 2019, with similar cash burns expected in the near future. Market potential by indication: $1.7 billion (relapsed/refractory CLL ... read more

3 Top Biotech Stocks to Buy in January

The deal will combine Bristol-Myers' and Celgene's core oncology and immunology segments ... This would include Celgene's multiple myeloma powerhouse Revlimid, which could soon become the top-selling ... read more

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

Checkpoint and TG Therapeutics ... Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a ... read more

Looking for another news?


2015, a Strategic Year for LFB

In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive ... and often rare diseases in the fields ... read more


Flare-responsive hydrogel developed to treat arthritis

"Although new therapeutics have been developed ... The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration's list of ... read more

Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene

Once Bristol-Myers Squibb completes its planned acquisition of Celgene, it will be an oncology powerhouse. Bristol-Myers Squibb ... for Bristol-Myers Squibb to become a top-five player in immunology a... read more

Uveitis Pipeline and Clinical Trials Review Research Reports for 2015

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment ... Drugs to Inhibit Aldose Red... read more

Deal Watch January 2018

Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop ... licence 380 Jiangsu Hengrui Medicine/TG Therapeutics BTK inhibitor ... read more

Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development

December 27, 2007 09:59 ET | Source: TG Therapeutics ... aesthetic and medical, dermatologic therapeutics. Prior to Revance, she was Senior Director, Medical Research, Immunology at Biogen Idec, Inc. ... read more

Investors Should Exercise Caution With REVO Biologics IPO

Dr. Echelard currently serves as a director of TG Therapeutics (NASDAQ: TGTX) and as a director of GTC Biotherapeutics UK Limited. Dr. Echelard received a Ph.D. in microbiology and immunology from the ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us